{
  "scenario_id": "biotechnology_gene_editing_clinical_trials_2025",
  "context": "Biotechnology research institution evaluating CRISPR-based gene editing for sickle cell disease treatment",
  "stakeholders": {
    "requester": "Principal Investigator",
    "approvers": ["Institutional Review Board", "Chief Scientific Officer", "Ethics Committee"],
    "influencers": ["Patient Advocacy Groups", "Regulatory Experts", "Clinical Trial Specialists"]
  },
  "request": {
    "amount": "$15,000,000",
    "purpose": "Conduct Phase 1/2 clinical trials for CRISPR gene editing therapy",
    "urgency": "medium",
    "justification": "Potential cure for genetic blood disorder affecting millions worldwide"
  },
  "decision_process": [
    {
      "stage": "ethical_review",
      "duration": "8 weeks",
      "activities": ["Bioethics consultation", "Patient consent framework development", "Societal impact assessment"],
      "outcome": "Ethical framework approved with enhanced oversight"
    },
    {
      "stage": "scientific_validation",
      "duration": "6 weeks",
      "activities": ["Preclinical data review", "Safety profile assessment", "Efficacy endpoint validation"],
      "outcome": "Scientific merit confirmed with conditional approval"
    },
    {
      "stage": "regulatory_navigation",
      "duration": "4 weeks",
      "activities": ["FDA consultation", "IND application preparation", "Regulatory risk assessment"],
      "outcome": "Approved for clinical trials with comprehensive monitoring plan"
    }
  ],
  "business_impact": {
    "expected_outcomes": ["First-in-human gene editing therapy", "Breakthrough treatment for sickle cell disease", "Platform technology for other genetic disorders"],
    "projected_roi": "Transformative medical advancement with potential for global health impact",
    "risk_factors": ["Off-target editing effects", "Immune responses to edited cells", "Long-term safety unknowns", "Regulatory approval challenges"]
  }
}